STERIS plc

STE · NYSE · USD

Can STERIS restart AST sterilization volume growth in the second half while funding record plant spending and a higher tax rate without stalling earnings growth?

Last 4 earnings calls · through Q1 FY2027

Bull case

  • Recurring revenue mix

    Service and consumable revenue keeps growing faster than equipment, so results depend less on the timing of large capital orders and more on installed base and procedure growth.

  • Pharma manufacturing reshoring

    Pharmaceutical customers are building and localizing manufacturing capacity again, which pulls through sterilizers, washers and chemistries into new aseptic plants.

  • Tariff cost stabilization

    Tariffs have moved from an escalating cost that limited the earnings outlook to a roughly flat expense, letting price and factory productivity reach the margin line.

  • Capital deployment capacity

    Cash generation funds a larger buyback, a growing dividend and a new chemistry plant at the same time, with debt well below the stated target range.

Bear case

  • AST inventory destocking

    Sterilization service volumes are soft because medical device customers are working down inventory, and management expects the improvement to arrive only later in the year.

  • Capital shipment timing

    Healthcare equipment revenue swings with shipment timing and order comparisons, so quarterly growth reflects when backlog converts rather than a change in hospital demand.

  • Rising capital spending

    Free cash flow guidance came down as STERIS starts several large plant projects, and a higher tax rate trims what share repurchases actually add to earnings.

  • Customer insourcing risk

    Hospital and device customers are consolidating and can build their own sterilization capacity, which limits pricing and volume control in the two largest segments.

Bull and bear points

Growth & Execution

In short: Service and consumables grow steadily, while AST sterilization volumes are soft.

Bull · 2

  • Service revenue is now the larger Healthcare base

    Repeat service and consumable sales depend on the installed fleet and procedure volumes rather than on hospitals approving large equipment budgets.

    Filed financials

  • Pharma reshoring moves from noise to real projects

    New aseptic plants in the U.S. need sterilizers, washers and chemistries, which gives Life Sciences capital equipment a multiyear source of orders.

    Tone shiftQ2 FY2026 → Q1 FY2027
Bear · 2

  • AST service growth slows on device destocking

    Management had confidently guided AST services to 9% to 10% growth and now describes global demand as soft, with improvement expected only in the second half.

    Tone shiftQ2 FY2026 → Q1 FY2027

  • Healthcare equipment orders turn negative

    Equipment revenue now depends on converting an existing backlog rather than on rising new demand, so a slip in shipments directly moves segment growth.

    Q3 FY2026 call

Profitability & Financial Strength

In short: Margins expand on price and productivity, but plant spending and tax cut cash returns.

Bull · 2

  • Gross margin rises on price and productivity

    Price and factory efficiency outrunning inflation is how mid single digit volume growth becomes double digit earnings growth at STERIS.

    Filed financials

  • Tariffs shift from drag to roughly neutral

    A cost that trimmed margins is now modeled as flat, so price and productivity improvements are no longer absorbed by rising import duties.

    Tone shiftQ3 FY2026 → Q4 FY2026
Bear · 2

  • Free cash flow guide cut on plant spending

    The company generated strong cash over the last twelve months, but management now guides this year lower because capital spending is stepping up.

    Q1 FY2027 call

  • Withholding tax raises the cost of cash returns

    Moving profit across borders to pay dividends and buy back shares triggers U.S. withholding tax, so each dollar returned to shareholders costs more than it used to.

    Q4 FY2026 call

Market Position

In short: Its products sit inside most hospital sites, though customers can insource sterilization.

Bull · 2

  • Procedures shifting to surgery centers

    Ambulatory surgery centers need new sterilization and disinfection capacity and more clinical support than large hospitals, which favors STERIS product and service packages.

    Q3 FY2026 call

  • Sterility assurance specified into customer systems

    When customers dual source sterility assurance to STERIS, the high-margin chemistries consumed by those installed units stay with the equipment base.

    Q4 FY2026 call
Bear · 2

  • Customers can insource sterilization work

    Device makers can build their own sterilization plants, and key AST inputs come from few suppliers, so volumes and input costs sit partly outside STERIS control.

    10-K, filed 2026-05-29

  • Ethylene oxide litigation continues

    STERIS still makes settlement payments tied to ethylene oxide emissions, and its AST plants remain exposed to injury claims even after the facility upgrades.

    10-K, filed 2026-05-29